Cardiovascular disease management during the coronavirus disease 2019 pandemic.
Cardiovascular disease management during the coronavirus disease 2019 pandemic. Int J Med Sci. 2020;17(10):1340-1344 Authors: Lee WH, Chen YC, Chen SC, Chen CJ, Hsu PC, Tsai WC, Chu CY, Lee CS, Lin TH, Voon WC, Kuo CH, Su HM Abstract Based on clinical presentation, pathophysiology, high infectivity, high cardiovascular involvement, and therapeutic agents with cardiovascular toxicity of coronavirus disease 2019 (COVID-19), regular cardiovascular treatment is being changing greatly. Despite angiotensin-converting enzyme 2 serving as the portal for infection, the continuation of clinically indicated renin-angiotensin-aldosterone blockers is recommended according to the present evidence. Fibrinolytic therapy can be considered a reasonable option for the relatively stable ST segment elevation myocardial infarction (STEMI) patient with suspected or known COVID-19. However, primary percutaneous coronary intervention is still the standard of care in patients with definite STEMI if personal protective equipment is available and cardiac catheterization laboratory has a good infection control. In patients with elevated cardiac enzymes, it is very important to differentiate patients with Type 2 myocardial infarction or myocarditis from those with true acute coronary syndromes because invasive percutaneous intervention management in the former may be unnecessary, especially if they are hemodynamically stable. Finally, patients with baseline QT prolongation or those ta...
Authors: Jothimani D, Daniel H, Danielraj S, Ramachandran H, Rela M PMID: 32738853 [PubMed - as supplied by publisher]
Authors: Pahlajani D PMID: 32738852 [PubMed - as supplied by publisher]
Authors: Naik S, Acharya V PMID: 32738851 [PubMed - as supplied by publisher]
Authors: Chopra HK, Hiremath SM, Wander GS, Kumar AS, Naik S PMID: 32738846 [PubMed - as supplied by publisher]
Conclusion: The prevalence of Abnormal Liver function tests in patients of COVID-19 is 59.04%. Abnormal liver functions were more in males. The average stay in hospital for COVID-19 patients with abnormal LFTs was longer than those with normal LFTs. PMID: 32738845 [PubMed - as supplied by publisher]
Conclusions: This hospital-based registry shows that mildly symptomatic or asymptomatic young covid-19 patients have excellent prognosis. PMID: 32738843 [PubMed - as supplied by publisher]
Conclusion: Lymphopenia is an effective and reliable indicator of onset of symptoms and severity of disease in COVID-19 patients. RDW was found to be higher in COVID 19 patients in comparison to normal patients, however it had no significant relationship with appearance of symptoms or severity of the disease. PMID: 32738839 [PubMed - as supplied by publisher]
Authors: Tiwaskar M, Vora A PMID: 32738833 [PubMed - as supplied by publisher]
AbstractCoronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is now a global pandemic with the highest number of affected individuals in the modern era. Not only is the infection inflicting significant morbidity and mortality, but there has also been a significant strain to the health care system and the economy. COVID-19 typically presents as viral pneumonia, occasionally leading to acute respiratory distress syndrome (ARDS) and death. However, emerging evidence suggests that it has a significant impact on the cardiovascular (CV) system by di rect myocardial da...
Abstract Coronaviruses (CoVs) possess an enveloped, single, positive-stranded RNA genome which encodes for four membrane proteins, namely spike (S), envelope (E), membrane (M) and nucleocapsid (N) proteins 3-5 . With regard to pathogenicity, S proteins are essential for viral entry into host cells [2, 3]. SARS-CoV binds to the angiotensin-converting enzyme (ACE)2 which is present on nonimmune cells, such as respiratory and intestinal epithelial cells, endothelial cells, kidney cells (renal tubules) and cerebral neurons and immune cells, such as alveolar monocytes/macrophages [4-6]. Of note, CD209L or liver/lymp...
More News: Angioplasty | Biomedical Science | Cardiac Catheterization | Cardiology | Cardiovascular | Coronary Angioplasty | Coronavirus | COVID-19 | Heart | Heart Attack | Hydroxychloroquine | Kaletra | Laboratory Medicine | Myocarditis | Norvir | Pandemics | Percutaneous Coronary Intervention | Toxicology